[Federal Register: August 20, 1999 (Volume 64, Number 161)]
[Notices]               
[Page 45566]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr20au99-115]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[DEA #179S2]

 
Controlled Substances: 1999 Aggregate Production Quota

AGENCY: Drug Enforcement Administration, (DEA), Justice.

ACTION: Final interim notice establishing a revised 1999 aggregate 
production quota.

-----------------------------------------------------------------------

SUMMARY: The interim notice 64 FR 29358, June 1, 1999, which revised 
the 1999 aggregate production quota for secobarbital, a Schedule II 
controlled substance in the Controlled Substances Act (CSA), is adopted 
without change.

DATES: This is effective on August 20, 1999.

FOR FURTHER INFORMATION CONTACT: Frank L. Sapienza, Chief, Drug and 
Chemical Evaluation Section, Drug Enforcement Administration, 
Washington, D.C. 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Section 306 of the CSA (21 U.S.C. 826) 
requires that the Attorney General establish aggregate production 
quotas for each basic class of controlled substance listed in Schedules 
I and II each year. This responsibility has been delegated to the 
Administrator of the DEA by Section 0.100 of Title 28 of the Code of 
Federal Regulations. The Administrator, in turn, has redelagated this 
function to the Deputy Administrator of the DEA pursuant to Section 
0.104 of Title 28 of the Code of Federal Regulations.
    On June 1, 1999, an interim notice establishing a revised 1999 
aggregate production quota for secobarbital was published in the 
Federal Register (64 FR 29358). All interested persons were invited to 
comment on or before July 1, 1999. No comments or objections were 
received and the interim notice is adopted without change.
    Therefore, under the authority vested in the Attorney General by 
Section 306 of the CSA (21 U.S.C. 826), delegated to the Administrator 
of the DEA by Section 0.100 of Title 28 of the Code of Federal 
Regulations, and redelegated to the Deputy Administrator, pursuant to 
Sec. 0.104 of Title 28 of the Code of Federal Regulations, the Deputy 
Administration hereby establishes the following revised 1999 aggregate 
production quota for the listed controlled substances, expressed in 
grams of anhydrous acid:

------------------------------------------------------------------------
                                                               Revised
                        Basic class                           1999 quota
------------------------------------------------------------------------
Secobarbital...............................................    1,011,000
------------------------------------------------------------------------

    The Office of Management and Budget has determined that notices of 
aggregate production quotas are not subject to centralized review under 
Executive Order 12866. This action has been analyzed in accordance with 
the principles and criteria contained in Executive Order 12612, and it 
has been determined that this matter does not have sufficient 
federalism implications to warrant the preparation of a Federalism 
Assessment.
    The Deputy Administrator hereby certifies that this action will 
have no significant impact upon small entities whose interests must be 
considered under the Regulatory Flexibility Act, 5 U.S.C. 601 et seq. 
The establishment of aggregate production quotas for Schedules I and II 
controlled substances is mandated by law and by international treaty 
obligations. The quotas are necessary to provide for the estimated 
medical, scientific, research and industrial needs of the United 
States, for export requirements and the establishment and maintenance 
of reserve stocks. While aggregate production quotas are of primarily 
importance to large manufacturers, their impact upon small entities is 
neither negative nor beneficial. Further, this action involves only one 
basic class of controlled substance. Accordingly, the Deputy 
Administrator has determined that this action does not require a 
regulatory flexibility analysis.

    Dated: August 11, 1999.
Donnie R. Marshall,
Deputy Administrator.
[FR Doc. 99-21582 Filed 8-19-99; 8:45 am]
BILLING CODE 4410-09-M